Abstract: A pesticidal protein class exhibiting toxic activity against Coleopteran, Lepidopteran, and Hemipteran pest species is disclosed, and includes, but is not limited to, TIC5290. DNA constructs are provided which contain a recombinant nucleic acid sequence encoding the TIC5290 pesticidal protein. Transgenic plants, plant cells, seed, and plant parts resistant to Lepidopteran, Coleopteran and Hemipteran infestation are provided which contain recombinant nucleic acid sequences encoding the TIC5290 pesticidal protein of the present invention. Methods for detecting the presence of the recombinant nucleic acid sequences or the protein of the present invention in a biological sample, and methods of controlling Coleopteran, Lepidopteran, and Hemipteran species pests using the TIC5290 pesticidal protein are also provided.

Abstract: The present invention is directed to C-type lectin-like molecule-1 (CLL1) specific ligand peptides, comprising the amino acid motif LR(S/T), and methods of their use, e.g., for imaging detection for diagnosis of leukemia and the presence of leukemic stem cells (LSCs) and targeted therapy against leukemia mediated at least in part by CLL1-expressing LSCs.

Abstract: The invention relates to a method to predict the response to treatment with radiotherapy combined with cisplatin-based chemotherapy in patients with cancer, preferably non-microcytic lung cancer, wherein said method is based on the detection of the presence of methylation in the IGFBP-3 gene. The present invention also relates to an in vitro method to design a customised treatment for an individual with said disease. The method of the invention may be quantitative or semi-quantitative. The present invention also relates to a probe designed for the quantitative detection of the methylation of the IGFBP-3 gene, to a kit that comprises it and to the use of the kit to predict the response of a subject to the aforementioned treatment.

Abstract: Methods and materials for modulating (e.g., increasing or decreasing) flavonoid levels in cacao plants are disclosed. For example, nucleic acids encoding flavonoid-modulating polypeptides are disclosed as well as methods for using such nucleic acids to transform plant cells. Also provided are methods for accelerating breeding of Theobroma cacao plants of the porcelana variety with modulated levels of proanthocyanidin, its precursors and it polymers, useful in various medical and skin care products. Also provided are plants having modulated flavonoid levels and plant products produced from plants having modulated flavonoid levels.

Abstract: The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated.

Abstract: The present invention relates to a transduced cancer cell line stably expressing a leukemia tumor antigen, wherein the cancer cell line is cervical cancer cells, breast cancer cells, ovarian cancer cells, pancreatic cancer cells, lung cancer cells, or glioblastoma cells. The transduced adherent cell line of the present invention is useful for many pre-clinical applications such as real time cytotoxicity assay or to test the effects of CAR-T cells that target the tumor antigen. The present invention is exemplified by Hela cell line stably expressing CD19.

Abstract: The present disclosure provides methods, kits, and compositions for detecting subject anti-HCV antibodies in a sample using NS3 capture peptides. In certain embodiments, at least two NS3 helicase (NS3h) capture peptides and at least two conjugate peptides (e.g., NS3h conjugate peptides) are employed together, which allows for a broad dynamic range of subject antibody detection in a one-step type assay. In other embodiments, methods are provided of detecting NS3-specific subject antibodies without the use of a reducing agent. In some embodiments, NS3-specific subject antibodies are detected with a ‘double shot’ of NS3 conjugate peptide (e.g., conjugate peptide added to a sample both before and after washing).

Abstract: The invention provides engineered diatoms and methods of producing oil using diatoms. The invention also provides methods of modifying the lipids quantity and/or quality produced by diatom organisms through genome engineering. Also provided are oils, fuels, oleochemicals, chemical precursors, and other compounds manufactured from such modified diatoms.

Abstract: The invention relates to a host cell comprising at least four different heterologous polynucleotides chosen from the group of polynucleotides encoding cellulases, hemicellulases and pectinases, wherein the host cell is capable of producing the at least four different enzymes chosen from the group of cellulases, hemicellulases and pectinases, wherein the host cell is a filamentous fungus and is capable of secretion of the at least four different enzymes. This host cell can suitably be used for the production of an enzyme composition that can be used in a process for the saccharification of cellulosic material.

Abstract: The present invention provides methods for producing a silk protein spinning dope solution suitable for producing high toughness fibers, the thus produced silk protein spinning dope solution, methods for producing fibers using said silk protein spinning dope solution.

Abstract: A peptide having activity to improve skin condition is described. The peptide exhibits a very excellent effect in improving skin condition by inhibiting MMP2 activity. A composition containing the peptide exhibits excellent biological activities, such as inhibiting collagen decomposition and melanosome migration, and thus can be used in wrinkle reduction, skin regeneration, skin elasticity improvement, anti-skin aging, wound regeneration, acne reduction, skin regeneration or skin whitening. The composition containing the peptide can be used as a pharmaceutical composition for preventing or treating MMP activity-related diseases and inflammation diseases.

Abstract: The present invention relates to the production and use of covalently closed circular (ccc) recombinant DNA molecules such as plasmids, cosmids, bacterial artificial chromosomes (BACs), bacteriophages, viral vectors and hybrids thereof, and more particularly to vector modifications that improve expression of these DNA molecules.

Abstract: Provided are colostrum and milk polypeptides recombinantly expressed in photosynthetic organisms containing colostrum and milk polypeptides, compositions comprising such organisms and methods for producing such organisms.

Abstract: The purpose of the present invention is to provide: a biomarker for psychiatric and neurological disorders, in particular, a biomarker for diagnosing psychiatric and neurological disorders; and a test kit and test method for psychiatric and neurological disorders. The inventors discovered that there is a significant increase in the concentration of free ? immunoglobulin chains and free ? immunoglobulin chains in the blood samples from patients with psychiatric and neurological disorders. Consequently, the present invention provides a biomarker for psychiatric and neurological disorders that includes at least one selected from the group consisting of free ? immunoglobulin chains, free ? immunoglobulin chains, and fragments thereof. Using this biomarker for psychiatric and neurological disorders enables the psychiatric and neurological disorders to be easily tested and diagnosed with the blood samples from the subjects.

Abstract: The invention provides a non-naturally occurring microbial organism having a muconate pathway having at least one exogenous nucleic acid encoding a muconate pathway enzyme expressed in a sufficient amount to produce muconate.

Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.

Abstract: The present specification discloses an immunogenic composition comprising polypeptide, wherein each of the polypeptides has no more than 100 amino acids, which polypeptides comprises one or more sequences having at least 60% homology with any of SEQ ID 1-4, or comprises two or more epitopes having 7 amino acids or more, each epitope having at least 60% homology with a sub-sequence of any of SEQ ID 1-4 that has the same length as the epitope, wherein, the polypeptide is immunogenic in a vertebrate expressing a major histocompatibility complex (MHC) allele, and wherein the polypeptide is not a complete HIV virus protein.

Abstract: The present invention relates generally to a method of modulating graft functionality. More specifically, the present invention relates to a method of downregulating the onset or progression of graft dysfunction by downregulating the functional level of activin. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterized by graft dysfunction, such as the primary graft dysfunction associated with organ transplantation.

Abstract: A mode of a polypeptide according to the present invention exhibits a fluorescence property, and has (1) an amino acid sequence represented by SEQ ID NO. 1 or NO. 2, (2) an amino acid sequence represented by SEQ ID NO. 1 or NO. 2 in which amino acid sequence 1 to 34 amino acids have been replaced or otherwise modified, (3) a sequence identity of 85% or more with respect to the amino acid sequence represented by SEQ ID NO. 1 or NO. 2, or (4) an amino acid sequence encoded by a polynucleotide that hybridizes under a stringent condition with a polynucleotide having a sequence complementary to a polynucleotide that encodes the polypeptide defined in (1).

Abstract: 5-hydroxytryptophan (5-HTP), a precursor of serotonin, is produced in a microbial host cell. A modified bacterial phenylalanine 4-hydroxylase (P4H) catalyzes the tryptophan 5-hydroxylation reaction. Optionally the host cell includes a cofactor regeneration mechanism, allowing continuous production of 5-HTP without supplementation of exogenous cofactors.

Abstract: A novel Bacillus thuringiensis crystal protein exhibiting insect inhibitory activity is disclosed. Growth of Lygus insects is significantly inhibited by providing the novel crystal protein in Lygus insect diet. Polynucleotides encoding the crystal protein, transgenic plants and microorganisms that contain the polynucleotides, isolated peptides derived from the crystal protein, and antibodies directed against the crystal protein are also provided. Methods of using the crystal protein and polynucleotides encoding the crystal protein to control Hemipteran insects are also disclosed.

Abstract: Embodiments herein include polynucleotides, vectors and methods for the insertion and expression of transgenes. In an embodiment, a polynucleotide is included. The polynucleotide can include a JeT promoter or variant thereof, an intron sequence less than 400 bases in length, and a polynucleotide sequence encoding a polypeptide or protein operatively linked to the promoter. In an embodiment, a recombinant vector is included. The recombinant vector can include a JeT promoter or variant thereof, an intron sequence less than 400 bases in length, and a polynucleotide sequence encoding a polypeptide or protein operatively linked to the promoter. Other embodiments are also included herein.

Abstract: Aspects of the invention include host cells that are engineered to produce benzylisoquinoline alkaloids (BIAs). The host cells include heterologous coding sequences for a variety of enzymes involved in synthetic pathways from starting compounds to BIAs of the host cell. Also provided are methods of producing the BIAs of interest by culturing the host cells under culture conditions that promote expression of enzymes encoded by the heterologous coding sequences of the host cells. Aspects of the invention further include compositions, e.g., host cells, starting compounds and kits, etc., that find use in methods of the invention.

Abstract: The invention is intended to improve xylose assimilation ability and ethanol fermentation ability in a xylose-assimilating yeast into which a xylose isomerase gene has been introduced. The amount of NADH produced by the recombinant yeast into which the xylose isomerase gene had been introduced as a result of the enzymatic reaction of acetohydroxy acid reductoisomerase is lowered.

Abstract: An object is to provide a thermotolerant yeast capable of assimilating xylose to produce ethanol or a mutant strain thereof and a method for producing ethanol by assimilation of xylose. There is used a yeast, Kluyveromyces marxianus strain No. 21 (accession number: NITE BP-01739), or a mutant strain thereof that has xylose assimilation ability and ethanol production ability when cultured at 30° C. under aerobic conditions using a culture medium containing xylose as a sugar source. Also performed is a method for producing ethanol, comprising culturing the yeast or the mutant strain thereof under aerobic conditions using a culture medium containing xylose as a sugar source.

Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

Abstract: There has been a demand for a codon-optimized gene for the mutated catalytic domain of Oplophorus luciferase, which is capable of efficiently expressing a protein both in a cultured animal cell and Escherichia coli. There has also been a demand for a substrate coelenterazine analog showing a higher activity than that of native 19 kDa protein. The invention provides a polynucleotide comprising a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 2. According to the invention, bis-coelenterazine is used as a substrate coelenterazine analog suitable for the photoprotein encoded by the polynucleotide comprising the polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 2.

Abstract: The invention relates to a lyase and a lyase-encoding DNA, to vectors containing the DNA and to a method for the asymmetric synthesis of (S)-phenylacetylcarbinol. According to the invention, a lyase is provided, in which tryptophan is replaced with an amino acid at position 543 in protein ApPDC-E469G, said protein being modified with respect to the wild type of Aceobacter pasteurianus, or in which it is less space-filling than tryptophan. According to the invention, deoxyribonucleic acids are furthermore provided, which encode the lyase. (S)-phenylacetylcarbinol can be produced with the lyase according to the invention from the educts benzaldehyde and pyruvate or acetaldehyde with an enantiomeric excess of at least 94%.

Abstract: Steviol glucosyltransferases and methods for producing steviol glycosides using the enzymes are provided. The present invention provides steviol glucosyltransferases and methods for producing steviol glycosides using the enzymes. The invention also provides transformants into which steviol glucosyltransferase genes are introduced and methods for preparing the transformants.

Abstract: The present invention relates to extracted plant lipid, comprising fatty acids in an esterified form.

Abstract: A modified laminin characterized in that a laminin or a heterotrimeric laminin fragment has a collagen binding molecule conjugated to at least one site selected from the ? chain N-terminus, the ? chain N-terminus and the ? chain N-terminus, and an extracellular-matrix material comprising the modified laminin, and collagen and/or gelatin serve as an alternative to Matrigel and are useful as an extracellular-matrix material for the formation of a safe three-dimensional tissue structure for regenerative medicine in humans.

Abstract: Various aspects and embodiments of the present disclosure relate to the purification antibodies by hydrophobic interaction chromatography under no-salt conditions.

Abstract: The present disclosure is directed to the biosynthetic pathway for a nonribosomal peptide synthetase (NRPS) derived drug and analogs thereof. The invention provides polynucleotide sequences useful for heterologous expression in a convenient microbial host for the synthesis of the NRPS-derived drug, the polypeptides encoded by such polynucleotides, expression vectors comprising the polynucleotides, host cells comprising the polynucleotides or expression vectors, and kits comprising a host cell. Also provided is a method for the production of ET-743, the NRPS-derived drug.

Abstract: A method of detecting genetic material deriving from Chlamydia trachomatis comprising detection of a specified nucleic acid sequence, optionally using specific primers and probes and optionally in combination with the detection of genetic material deriving from Pectobacterium atrosepticum as an internal control; and related products and kits.

Abstract: A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.

Abstract: Disclosed are peptides that exhibit good binding to the anticodon stem and loop of human lysine tRNA species, tRNALys3. The starting point was the 15-amino-acid sequence, RVTHHAFLGAHRTVG, found to bind selectively to hypermodified tRNALys3. The peptide backbone conformation was determined via atomistic simulation of the peptide-ASLLys3complex and then held fixed throughout the search. Analysis of the binding structure and the various contributions to the binding energy shows that: 1) two hydrophilic residues (asparagine (ASN) at site 11 and the cysteine (CYS) at site 12) “recognize” the ASLLys3 due to the VDW energy, and thereby contribute to its binding specificity, and 2) the positively-charged arginines (ARG) at sites 4 and 13 preferentially attract the negatively-charged sugar rings and the phosphate linkages, and thereby contribute to the binding affinity.

Abstract: The present invention provides a cell for use in a one-step cell-based assay for an extracellular ligand (e.g., IFN?) that initiates a ligand-specific signal at the nucleus of the cell and for neutralizing antibodies against the extracellular ligand. The cell-based one-step assay allows both the extracellular ligand concentration and the neutralizing antibody titer to be quantified in a single sample (e.g., serum) without the need for sample dilution and addition of exogenous extracellular ligand.

Abstract: The present invention relates to the field of RNA-mediated gene silencing in insect species. The present invention is based, in part, on the inventors' sequencing of genes from eucalyptus invasive species gall wasp pests Leptocybe invasa (Li) and Ophelimus maskelli (Om). In certain aspects, the invention provides Li and Om nucleic acids, derivatives thereof and the use of such nucleic acids and derivatives as gall wasp control agents.

Abstract: The present disclosure relates to bioengineering approaches for producing biofuel and, in particular, to the use of a C1 metabolizing microorganism reactor system for converting C1 substrates, such as methane or methanol, into biomass and subsequently into biofuels, bioplastics, or the like.

Abstract: A composition having tissue repair activity, which is capable of promoting reactions associated with tissue repair, contains at least one selected from the group consisting of a first component that is a protein having a monocyte chemotactic protein-1 (MCP-1) activity, a second component that is a protein having the extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), and a third component that is at least one of chondroitin sulfate and chondroitin sulfate proteoglycan.

Abstract: The invention relates to a genetically engineered bacterium having an enzyme that converts acetyl-CoA to acetoacetyl-CoA, an enzyme that converts acetoacetyl-CoA to 3-hydroxybutyryl-CoA, and an enzyme that converts 3-hydroxybutyryl-CoA to 3-hydroxybutyrate. The bacterium may also have enzymes to produce other downstream products, such as 3-hydroxybutyryaldehyde, and 1,3-butanediol. Typically, the bacterium is capable of producing these products from a gaseous substrate, such as syngas or an industrial waste gas.

Abstract: This document describes biochemical pathways for producing glutaric acid, 5-aminopentanoic acid, 5-hydroxypentanoic acid, cadaverine or 1,5-pentanediol by forming one or two terminal functional groups, comprised of carboxyl, amine or hydroxyl group, in a C5 backbone substrate such as 2-oxoglutarate.

Abstract: The present disclosure teaches the protection of plants and human and non-human subjects from pathogens. The present disclosure enables a multivalent approach to inhibiting pathogen infection in plant and human and non-human animal subjects and to ameliorate damage to susceptible subjects.

Abstract: The present invention is directed to isolated polypeptides and antibodies suitable for producing therapeutic preparations, methods, and kits relating to bone deposition. One objective of the present invention is to provide compositions that improve bone deposition. Yet another objective of the present invention is to provide methods and compositions to be utilized in diagnosing bone dysregulation. The therapeutic compositions and methods of the present invention are related to the regulation of Wise, Sost, and closely related sequences. In particular, the nucleic acid sequences and polypeptides include Wise and Sost as well as a family of molecules that express a cysteine knot polypeptide.

Abstract: A method for treating an individual at risk for a complement-associated disorder is provided, the method including: (a) obtaining a sample of a body fluid from the individual; (b) measuring a complement activation level in the sample via a point-of-care lateral flow immunoassay; (c) correlating the complement activation level in the sample to a risk of a complement-associated disorder by comparing the complement activation level in the sample to a reference level in a control, wherein a deviation in complement activation level in the sample compared to the reference level in the control indicates the individual is at risk for a complement-associated disorder; (d) selecting a treatment for the individual, based on the correlating of step (c); and (e) treating the individual with the treatment selected in accordance with step (d).

Abstract: The present disclosure relates generally to therapeutic compositions comprising recombinant bacteria. Further, the disclosure elaborates upon methods of utilizing the taught therapeutic compositions to treat autoimmune and inflammatory disease. The present teachings also relate to the disclosed recombinant bacteria and methods of producing the recombinant bacteria utilized in the compositions and methods. Further taught herein are dietary supplements and food additive compositions comprising the taught recombinant bacteria.

Abstract: Methods for enhanced yeast fermentation of plant material through the genetic modification of yeast comprising stably integrating into a yeast an inducible promoter operably linked to a mitochondrial targeting signal as well as at least one restriction enzyme and inducing the expression of the at least one restriction enzyme, wherein the restriction enzyme targets and destroys the mitochondrial DNA of the yeast. DNA constructs comprising at least an inducible promoter operably linked to a mitochondrial targeting signal as well as at least one restriction enzyme for induced expression of at least one restriction enzyme for destruction of mitochondrial DNA as well as transgenic yeast expressing a DNA construct for destruction of mitochondrial DNA and enhanced fermentation, are also disclosed.

Abstract: Compositions effective for treating or preventing an anthrax infection in a subject in need thereof and recombinant proteins included in the compositions are provided. Methods for producing recombinant proteins in plants are described. Transgenic plants engineered to produce recombinant proteins as well as genetic constructs comprising nucleic acids encoding recombinant proteins thereof are also described. Methods of protecting subjects against anthrax infection with plant-derived compositions are provided.

Abstract: An activation tagging construct for maize that includes one or more sugarcane bacilliform viral (SCBV) enhancer elements, and resulting tagged populations and plants, are described. In one example, an activation tagging DNA construct includes a coding sequence for a transposase, a detectable reporter (such as anthocyanin regulatory genes B-Peru and C1) and a non-autonomous transposable T-DNA cassette. For example, the transposable T-DNA cassette is inserted into the detectable reporter encoding region such that the B-Peru and C1 genes express anthocyanins in a cell containing the maize activation tagging DNA construct only upon excision of the transposable cassette. Methods of generating a tagged population of maize plants include transforming a maize plant cell or tissue with the disclosed constructs.

Abstract: A method for the in vitro diagnosis of colorectal cancer by determining the presence of the Ezrin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer using at least one anti-Ezrin monoclonal antibody directed against an Ezrin epitope chosen from the epitopes of sequence SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4+SEQ ID No.5, SEQ ID No.6+SEQ ID No.7 and SEQ ID No.8. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.